Author

Maryam Clausen

AstraZeneca (Sweden)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Systems Biology· 2 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Adil MardinoğluiD· 2 shared Jan BoréniD· 2 shared Johannes Wikström· 2 shared Malin C. LeviniD· 2 shared Mohammad Bohlooly‐YiD· 2 shared Muhammad ArifiD· 2 shared Abdel Wahad Bidar· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Adil MardinoğluORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Systems BiologyiSciencePeer-reviewedJun 12, 2026

Integrative Analysis of Left Ventricle and Epicardial Adipose Tissue Identifies SDHA and OGDH as Candidate Targets for Ischemic Heart Disease

Muhammad Arif, Stephen Doran, Maryam Clausen…·Jan Borén

DOI 10.1016/j.isci.2026.116370

𝕏 PostBluesky

Systems BiologyeLifePeer-reviewedMay 10, 2021

Integrative transcriptomic analysis of tissue-specific metabolic crosstalk after myocardial infarction

Muhammad Arif, Martina Klevstig, Rui Benfeitas…·Jan Borén

The paper analyzes transcriptomic changes in heart and other metabolically active tissues after myocardial infarction in mice, identifying common and tissue-specific biological responses.

47 citations

mousebulk RNA-seq

𝕏 PostBluesky

GenomicsbioRxivPreprintApr 6, 2020

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal…·Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

2 citations

𝕏 PostBluesky